West Pharmaceutical Services (WST) Long-Term Deferred Tax (2016 - 2026)
West Pharmaceutical Services has reported Long-Term Deferred Tax over the past 18 years, most recently at $63.9 million for Q1 2026.
- Quarterly Long-Term Deferred Tax rose 145.77% to $63.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $63.9 million through Mar 2026, up 145.77% year-over-year, with the annual reading at $38.4 million for FY2025, 47.69% up from the prior year.
- Long-Term Deferred Tax was $63.9 million for Q1 2026 at West Pharmaceutical Services, up from $38.4 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $99.0 million in Q1 2023 and troughed at $17.3 million in Q3 2023.
- The 5-year median for Long-Term Deferred Tax is $37.6 million (2024), against an average of $44.6 million.
- Biggest five-year swings in Long-Term Deferred Tax: plummeted 78.79% in 2024 and later surged 145.77% in 2026.
- Tracing WST's Long-Term Deferred Tax over 5 years: stood at $65.6 million in 2022, then crashed by 60.82% to $25.7 million in 2023, then increased by 1.17% to $26.0 million in 2024, then skyrocketed by 47.69% to $38.4 million in 2025, then skyrocketed by 66.41% to $63.9 million in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $63.9 million, $38.4 million, and $27.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.